R & D

OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial

 This material is intended to notify the press release issued on February 8 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.